Physostigmine

Overview

A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.

Indication

For the treatment of glaucoma, and in the treatment of severe anticholinergic toxicity.

Associated Conditions

Anticholinergic Syndrome

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome	2017/03/27	NCT03090620	Phase 4	Completed	University of Colorado, Denver
Anticholium® Per Se	2017/01/06	NCT03013322	Not Applicable	Completed	University Hospital Heidelberg
Evaluation if Physostigmine Reduces Symptoms in Patients Who Has Developed a Delirium in Intensive Care After a Surgery	2014/08/13	NCT02216266	Phase 3	UNKNOWN	PD Dr. Bertram Scheller
Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors	2013/12/11	NCT02008292	Not Applicable	Completed	Yale University
Pilot Study of Physostigmine-Enhanced Opioid Analgesia	2011/07/14	NCT01394445	Phase 3	Completed	Medical University of Graz
Phamacological Reversal of Airway Instability During Sedation	2010/07/28	NCT01171118	Not Applicable	Completed	University of Rochester
The Effect of Physostigmine on Cognitive Functioning in the Immediate Period After Sedation for Colonoscopy	2010/05/12	NCT01121497	Not Applicable	UNKNOWN	Rabin Medical Center
Physostigmine After General Anesthesia	2009/02/25	NCT00850850	Not Applicable	UNKNOWN	Bispebjerg Hospital
Pharmacological Intervention in Insulin Resistance Targeting Autonomic Nerve Activity	2008/06/03	NCT00689208	Early Phase 1	Completed	AstraZeneca

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

AI-Powered Research

Premium Access